Drug companies lose hundreds of millions of dollars when large-scale human clinical trials fail. Helen Pearson examines whether alternative procedures could help avoid such disappointments.
This is a preview of subscription content, log in via an institution to check access.
Related links
Related links
Related links in Nature Research
Stroke makes smokers forget their addiction
Brain can be made to self-repair
Drive for drugs leads to baby clinical trials
Personalized medicine prompts push to redesign clinical trials
Related external links
Rights and permissions
About this article
Cite this article
The bitterest pill. Nature 444, 532–533 (2006). https://doi.org/10.1038/444532a
Published:
Issue Date:
DOI: https://doi.org/10.1038/444532a
- Springer Nature Limited
This article is cited by
-
A Review of Human Pluripotent Stem Cell-Derived Cardiomyocytes for High-Throughput Drug Discovery, Cardiotoxicity Screening, and Publication Standards
Journal of Cardiovascular Translational Research (2013)
-
Drug repositioning for personalized medicine
Genome Medicine (2012)
-
Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain
Nature (2012)
-
Induced pluripotent stem cells — opportunities for disease modelling and drug discovery
Nature Reviews Drug Discovery (2011)
-
The beautiful cell: high-content screening in drug discovery
Analytical and Bioanalytical Chemistry (2010)